drugset / Trial / NCT02334293
Omegaven® as Parenteral Nutrition
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if a fat emulsion comprised of omega-3 fatty acids, Omegaven, would be beneficial in the management of steatotic liver injury in parenteral nutrition (PN) by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum.
Timeline
- Start
- 2013-10
- Primary completion
- 2017-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omegaven | Other / unclassified | — | — |